Amphastar Pharmaceuticals (AMPH) vs Bausch Health Companies (BHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amphastar Pharmaceuticals (AMPH) has outperformed Bausch Health Companies (BHC) over the past year, losing 1.1% versus a loss of 3.8%. Over five years, AMPH leads with a +33.6% price change compared with -78.4% for BHC. Bausch Health Companies is the larger company by market cap ($2.27 billion vs $1.11 billion), about 2.1 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 8.2x for Amphastar Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | BHC |
|---|---|---|
| Share price | $26.01 | $6.08 |
| Market cap | $1.11B | $2.27B |
| 1-day change | +1.84% | -1.22% |
| YTD return | -4.63% | -11.51% |
| 1-year return | -1.12% | -3.76% |
| 5-year return | +33.65% | -78.41% |
| P/E ratio (TTM) | 15.39 | — |
| Forward P/E | 8.18 | 1.45 |
| EPS (TTM) | $1.69 | $-2.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.52 | $8.00 |
| 52-week low | $16.65 | $4.33 |
| Distance from 52-week high | -11.89% | -24.06% |
| Analyst consensus | none | hold |
| Avg. price target upside | -13.49% | +23.46% |
| Average volume | 472.61K | 3.24M |
| Shares outstanding | 42.54M | 373.99M |
| Employees | 1,976 | 20,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bausch Health Companies is about 2.1 times larger than Amphastar Pharmaceuticals by market value ($2.27B vs $1.11B).
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
AMPH vs BHC FAQ
Which is bigger, Amphastar Pharmaceuticals or Bausch Health Companies?
Bausch Health Companies (BHC) is larger, with a market capitalization of $2.27B compared with $1.11B for Amphastar Pharmaceuticals (AMPH).
Which stock has performed better over the past year, AMPH or BHC?
AMPH returned -1.12% over the past 12 months, compared with -3.76% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and Bausch Health Companies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.